Literature DB >> 16534016

New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md.

William R Hiatt1, Steven E Nissen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16534016     DOI： 10.1161/CIRCULATIONAHA.105.607630

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  3 in total

1.  Canadian Cardiovascular Society Consensus Conference update on cardiac transplantation 2008: Executive Summary.

Authors:  H Haddad; D Isaac; J F Legare; P Pflugfelder; P Hendry; M Chan; B Cantin; N Giannetti; S Zieroth; M White; W Warnica; K Doucette; V Rao; A Dipchand; M Cantarovich; W Kostuk; R Cecere; E Charbonneau; H Ross; N Poirier
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

Review 2.  Renal effects of targeted anticancer therapies.

Authors:  Camillo Porta; Laura Cosmai; Maurizio Gallieni; Paolo Pedrazzoli; Fabio Malberti
Journal:  Nat Rev Nephrol       Date:  2015-03-03       Impact factor: 28.314

3.  EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.

Authors:  Kenneth S Chen; Nicholas J Fustino; Abhay A Shukla; Emily K Stroup; Albert Budhipramono; Christina Ateek; Sarai H Stuart; Kiyoshi Yamaguchi; Payal Kapur; A Lindsay Frazier; Lawrence Lum; Leendert H J Looijenga; Theodore W Laetsch; Dinesh Rakheja; James F Amatruda
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.